Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Aug 17 2016

• By Emily Hayes

Related Content

Amgen’s Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors

Apr 04 2016

PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis

Sep 14 2015

Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions

Jan 26 2015

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Aug 05 2016

Amgen Plugs Away On Repatha, With Hope For New Monthly Product

Jul 28 2016

PCSK9 Sponsors, Payers In The Ring At ACC

Apr 11 2016

Related Companies

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Express Scripts Holding Company

Merck & Co., Inc.

Additional Topics

Cost Effectiveness Reimbursement Commercial Cardiovascular BioPharmaceutical

More from Drug Pricing

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window